Browse by Person

Export as [feed] Atom [feed] RSS
Group by: Item Type | No Grouping
Number of items: 8.

Article

Craig, Z orcid.org/0000-0001-9930-6648, Swain, J, Batman, E et al. (16 more authors) (2020) NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 10 (2). e034527. ISSN 2044-6055

Papaxoinis, G, Kamposioras, K, Weaver, JMJ et al. (7 more authors) (2019) The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study. Journal of Gastrointestinal Surgery, 23 (9). pp. 1729-1741. ISSN 1091-255X

Smyth, EC, Rowley, S, Cafferty, FH et al. (17 more authors) (2019) Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial. JAMA Oncology, 5 (8). pp. 1181-1187. ISSN 2374-2437

Cunningham, D, Stenning, SP, Smyth, EC et al. (15 more authors) (2017) Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncology, 18 (3). pp. 357-370. ISSN 1470-2045

Propper, D, Jones, K, Anthoney, DA et al. (8 more authors) (2016) Phase II study of TP300 in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma. BMC Cancer, 16 (1). 779. ISSN 1471-2407

Smyth, E, Rowley, S, Allum, W et al. (17 more authors) (2016) A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948). Annals of Oncology, 27 (suppl_6). LBA26. ISSN 0923-7534

Proceedings Paper

Athauda, A, Nankivell, MG, Langley, RE et al. (17 more authors) (2019) Impact of age and sex on chemotherapy (CTx) efficacy, toxicity and survival in early oesophagogastric (OG) cancer: A pooled analysis of 3265 patients from four large randomised trials (OE02, OE05, MAGIC & ST03). In: Journal of Clinical Oncology. Annual Meeting of the American Society of Clinical Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology (ASCO) .

McNamara, MG, Swain, J, Craig, Z et al. (11 more authors) (2019) NET-02: A multi-center, randomised, phase II trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients (pts) with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma (PD-EP-NEC). In: Journal of Clinical Oncology. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), 31 May - 04 Jun 2019, Chicago, IL, USA. American Society of Clinical Oncology .

This list was generated on Sat Jan 1 16:10:06 2022 GMT.